Trial Profile

Prevention of Datopotamab Deruxtecan (TROP-2 Directed ADC) Associated Stomatitis in Patients With HER2-negative Metastatic Breast Cancer or Non-small Cell Lung Cancer Using Dexamethasone Mouthwash: a Single-arm, Phase 2 Trial (TROPION- DM, 2023-ESR-000087)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Datopotamab deruxtecan (Primary) ; Dexamethasone (Primary)
Indications Advanced breast cancer; Male breast cancer; Non-small cell lung cancer; Stomatitis; Triple negative breast cancer
Focus Therapeutic Use
Acronyms TROPION- DM

24 Oct 2025 Status changed from not yet recruiting to recruiting.
15 Aug 2025 Planned initiation date changed from 31 Jul 2025 to 31 Aug 2025.
22 Jun 2025 Planned initiation date changed from 31 May 2025 to 31 Jul 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com